Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Keytruda may have won the battle of European approval in metastatic esophageal cancer against Opdivo, but the war will be judged in the adjuvant setting, says GlobalData

Following today’s news (29 June) that Merck & Co’s Keytruda received EMA approval for patients with esophageal cancer (EC) or HER2-negative gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 combined positive score (CPS ≥10); Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst at GlobalData, a leading data, and analytics company, offers his view: “When combined with chemotherapy, […]
Read more

Overactive Bladder market characterized by significant untapped potential, says GlobalData

Untapped potential within the overactive bladder (OAB) market remains considerable due to under-diagnosis and under-treatment of this highly prevalent condition, according to GlobalData, a leading data and analytics company. Key opinion leaders (KOLs) interviewed by GlobalData verified that only a minority of patients with OAB, a symptom complex characterized by urinary urgency, with or without […]
Read more

Rapid-acting Sage Therapeutics and Biogen’s zuranolone could alter way depression is treated, says GlobalData

Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modulator, antidepressant zuranolone. Zuranolone could alter the way major depressive disorder (MDD) is treated with a focus on episodic treatment instead of maintenance treatment, says GlobalData, a leading data and analytics company. Philippa […]
Read more

China biopharma firms eye partnerships with western counterparts to promote indigenous drugs, says GlobalData

Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a leading data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the promotion rights to […]
Read more

Novavax’s COVID-19 vaccine may face severe uptake challenges in the US

Novavax has further demonstrated excellent results from its pivotal PREVENT-19 vaccine trial. Despite this positive data, it will likely see very little uptake in the US, says GlobalData, a leading data and analytics company. Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, comments: “Novavax’s PREVENT-19 trial enrolled close to 30,000 participants across 119 sites in the […]
Read more

CARsgen’s novel pipeline therapy could be beneficial to underserved patients in late-stage advanced HCC, says GlobalData

CARsgen Therapeutics’ novel pipeline therapy for advanced hepatocellular carcinoma (HCC) stands out in the American Society of Clinical Oncology (ASCO) virtual annual meeting for being the first-in-class approach with a unique mechanism of action that targets heavily pretreated advanced HCC patients, says GlobalData, a leading data and analytics company. Results for multiple HCC clinical trials […]
Read more

AstraZeneca, Pfizer, Roche lead non-small cell lung cancer digital marketing space in Japan, finds GlobalData

The non-small cell lung cancer (NSCLC) treatment landscape in Japan looks very mature with multiple drugs approved for targeted therapy, immunotherapy and chemotherapy. In this well-established market, several companies are active on digital channels to support NSCLC patients, amongst which AstraZeneca, Pfizer and Roche are the leaders, observes GlobalData, a leading data and analytics company. […]
Read more

Latest patent reforms to further bolster innovative pharma research in China, says GlobalData

China has made its latest patent amendments effective from June 01, 2021, reforms which are likely to ensure protection against untimely and unfair generic competition. As a result, the Chinese pharmaceutical market makes itself further competitive and conducive for innovative research companies, both regional and international, says GlobalData, a leading data and analytics company. Although […]
Read more

Global oncology Phase II clinical trials heavily impacted by COVID-19 disruptions, says GlobalData

Companies and organizations continue to report clinical trial disruptions across the globe due to the COVID-19 pandemic. These disruptions are being caused by a number of factors including delayed initiation, enrollment suspension, and slow enrollment, according to GlobalData, a leading data and analytics company. GlobalData’s recent global survey of key opinion leaders in the pharma […]
Read more

Dental devices market to rebound in 2021 as acquisitions rise

The COVID-19 pandemic saw certain markets such as anesthesia and respirator devices grow in 2020, while many others such as dental devices stagnated or saw a huge decline. However, dental devices are projected to make a strong recovery in 2021. The global market value for dental devices in 2021 is estimated to be $20.5bn, up […]
Read more

Interim data from UK study ‘Com-COV’ suggest higher reactogenicity

Preliminary safety results from the Oxford led Phase II Com-COV trial investigating immune responses in patients given heterologous prime-boost vaccine schedules indicate that mixing vaccines leads to higher reactogenicity and more frequent side effects, observes GlobaData, a leading data and analytics company. Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, comments: “The preliminary safety results may […]
Read more
1 … 62 63 64 65 66 … 110